Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of muscle disease (myopathy).

Background: Vitamin D deficiency has been proposed to have a role in the development and course of Graves' disease (GD).

Muscle weakness and quality of life (QoL) impairments are shared features of GD and vitamin D deficiency.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Body Composition, Dietary Supplements, Graves Disease, Muscle Strength, Muscle, Skeletal, Quality of Life and Vitamin D.

The authors tagged it with the keywords Graves' disease and thyrotoxicosis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with muscle disease (myopathy).

The publication is from 2020 (Thyroid : official journal of the American Thyroid Association), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Muscle disease (myopathy) research.